Bortezomib, rituximab, and dexamethason (BORID) is an active salvage regimen for patients with relapsed/refractory mantle cell lymphoma

被引：0
|
作者：
Drach, J. [1 ]
Kaufmann, H. [1 ]
Pichelmayer, O. [1 ]
Sagaster, V. [1 ]
Holzer, S. [1 ]
Zielinski, C. [1 ]
Raderer, M. [1 ]
机构：
[1] Med Univ Vienna, Div Clin Oncol, Dept Med 1, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：214 / 214
页数：1
相关论文
共 50 条
  • [1] Promising activity of bortezomib, rituximab, and dexamethason (BORID) in patients with relapsed mantle cell lymphoma
    Drach, J
    Seidl, S
    Pichelmayer, O
    Kaufmann, H
    Zielinski, C
    Raderer, M
    BLOOD, 2005, 106 (11) : 280B - 280B
  • [2] Bortezomib, rituximab, and dexamethason (BORID) as salvage treatment in relapsed/refractory mantle cell lymphoma: Sustained disease control in patients achieving a complete remission
    Drach, Johannes
    Kaufmann, Hannes
    Pichelmayer, Oskar
    Sagaster, Verena
    Holzer, Sonja
    Odelga, Viktoria
    Zielinski, Christoph
    Raderer, Markus
    BLOOD, 2007, 110 (11) : 760A - 760A
  • [3] Bortezomib, rituximab,and dexamethason (BORID) induces high response ratesand durable complete remissions in patients with relapsed/refractory mantle cell lymphoma
    Drach, J.
    Kaufmann, H.
    Pichelmayer, O.
    Sagaster, V.
    Seidl, S.
    Zielinski, C.
    Chott, A.
    Raderer, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 435 - 435
  • [4] Marked activity of, bortezomib, rituximab, and dexamethason in relapsed and refractory mantle cell lymphoma.
    Drach, Johannes
    Kaufmann, Hannes
    Pichelmayer, Oskar
    Sagaster, Verena
    Seidl, Sonja
    Chott, Andreas
    Zielinski, Christoph
    Raderer, Markus
    BLOOD, 2006, 108 (11) : 779A - 779A
  • [5] Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma
    Lamm, Wolfgang
    Kaufmann, Hannes
    Raderer, Markus
    Hoffmann, Martha
    Chott, Andreas
    Zielinski, Christoph
    Drach, Johannes
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (07): : 1008 - 1014
  • [6] BORID REGIMEN IN PATIENTS WITH MANTLE CELL LYMPHOMA
    Erdogan, I.
    Eskazan, A. E.
    Ercelebi, D. Cuhadar
    Berk, S.
    Yalniz, F. F.
    Elverdi, T.
    Salihoglu, A.
    Ar, M. C.
    Aydin, S. Ongoren
    Baslar, Z.
    Aydin, Y.
    Tuzuner, N.
    Soysal, T.
    HAEMATOLOGICA, 2015, 100 : 711 - 712
  • [7] Fludarabine, Bortezomib, Myocet® and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma
    Orciuolo, Enrico
    Buda, Gabriele
    Pelosini, Matteo
    Petrini, Mario
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 148 (05) : 810 - 812
  • [8] Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma
    Baiocchi, Robert A.
    Alinari, Lapo
    Lustberg, Mark E.
    Lin, Thomas S.
    Porcu, Pierluigi
    Li, Xiaobai
    Johnston, Jeffrey S.
    Byrd, John C.
    Blum, Kristie A.
    CANCER, 2011, 117 (11) : 2442 - 2451
  • [9] Rituximab Plus Gemcitabine and Oxaliplatin as Salvage Therapy In Patients with Relapsed/Refractory Mantle-Cell Lymphoma
    Gironella, Mercedes
    Lopez, Andres
    Pau, Abrisqueta
    Anny, Jaramillo
    Noelia, Purroy
    Bosch, Francesc
    BLOOD, 2010, 116 (21) : 1165 - 1165
  • [10] Rituximab Plus Gemcitabine and Oxaliplatin As Salvage Therapy in Patients with Relapsed/Refractory Mantle-Cell Lymphoma
    Gironella, Mercedes
    Lopez, Andres
    Merchan, Brayan
    Abrisqueta, Pau
    Jaramillo, Anny
    Bosch, Francesc
    BLOOD, 2012, 120 (21)
12345